| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 in Resistance to Thyroid Hormone: Study in Mice with a Targeted Mutation in the TRß Gene and Deficient in TR
1
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4264
Address all correspondence and requests for reprints to: Dr. Sheue-yann Cheng, Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892-4264. E-mail: sycheng{at}helix.nih.gov.
Resistance to thyroid hormone (RTH) is caused by mutations of the thyroid hormone receptor ß (TRß) gene. Almost all RTH patients are heterozygous with an autosomal dominant pattern of inheritance. That most are clinically euthyroid suggests a compensatory role of the TR
1 isoform in maintaining the normal functions of thyroid hormone (T3) in these patients. To understand the role of TR
1 in the manifestation of RTH, we compared the phenotypes of mice with a targeted dominantly negative mutant TRß (TRßPV) with or without TR
1. TRßPV mice faithfully recapitulate RTH in humans in that these mice demonstrate abnormalities in the pituitary-thyroid axis and impairment in growth. Here we show that the dysregulation of the pituitary-thyroid axis was worsened by the lack of TR
1 in TRßPV mice, and severe impairment of postnatal growth was manifested in TRßPV mice deficient in TR
1. Furthermore, abnormal expression patterns of T3-target genes in TRßPV mice were altered by the lack of TR
1. These results demonstrate that the lack of TR
1 exacerbates the manifestation of RTH in TRßPV mice. Therefore, TR
1 could play a compensatory role in mediating the functions of T3 in heterozygous patients with RTH. This compensatory role may be especially crucial for postnatal growth.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
C. S. Kim, H. Ying, M. C. Willingham, and S.-y. Cheng The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer Carcinogenesis, May 1, 2007; 28(5): 932 - 939. [Abstract] [Full Text] [PDF] |
||||
![]() |
Genetically Modified Animals in Endocrinology Endocr. Rev., December 1, 2005; 26(7): 985 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. O'Shea, J. H. D. Bassett, S. Sriskantharajah, H. Ying, S.-y. Cheng, and G. R. Williams Contrasting Skeletal Phenotypes in Mice with an Identical Mutation Targeted to Thyroid Hormone Receptor {alpha}1 or {beta} Mol. Endocrinol., December 1, 2005; 19(12): 3045 - 3059. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ying, F. Furuya, M. C. Willingham, J. Xu, B. W. O'Malley, and S.-y. Cheng Dual Functions of the Steroid Hormone Receptor Coactivator 3 in Modulating Resistance to Thyroid Hormone Mol. Cell. Biol., September 1, 2005; 25(17): 7687 - 7695. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Ortiga-Carvalho, K. Hashimoto, C. C. Pazos-Moura, D. Geenen, R. Cohen, R. M. Lang, and F. E. Wondisford Thyroid Hormone Resistance in the Heart: Role of the Thyroid Hormone Receptor {beta} Isoform Endocrinology, April 1, 2004; 145(4): 1625 - 1633. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |